

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

Claim 1 (original): Use of one or more synthetic CRH-R1 antagonists and /or CRH-R2 agonists for the treatment of an inflammatory disease or condition associated to activation, deactivation, differentiation and apoptosis of macrophages.

Claim 2 (original): Use according to claim 1, wherein the one or more synthetic CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.

Claim 3 (currently amended): Use according to claim 1-~~or 2~~, wherein the inflammatory disease or condition is chronic inflammatory bowel disease, idiopathic inflammatory disorder, inflammatory disorders of connective tissues, inflammatory demyelinating polyneuropathies, inflammatory myopathies, inflammatory diseases of joints including bursitis, the fibromyalgia syndrome and inflammatory diseases of upper gastrointestinal tract.

Claim 4 (original): Pharmaceutical composition comprising one or more synthetic CRH-R1 antagonists and /or CRH-R2 agonists.

Preliminary Amendment  
SUGHRUE MION, PLLC Ref: Q87992

Claim 5 (original): Pharmaceutical composition according to claim 4, wherein the composition is formulated for local or systemic administration.

Claim 6 (currently amended): Pharmaceutical composition according to claim 4 or 5, wherein the composition further comprises usual excipients such as diluents, fillers, binders, disintegrants, lubricants, conserving agents, flavourings and colourings.

Claim 7 (currently amended): Pharmaceutical composition according to ~~any of the claims~~ ~~claim 4 to 6~~, wherein the formulation is formulated for oral, parenteral or in-tradermal administration.

Claim 8 (original): Pharmaceutical composition according to claim 7, wherein the composition is formulated as an injection liquid.

Claim 9 (currently amended): Pharmaceutical composition according to ~~any of the claims~~ ~~claim 4 to 8~~, wherein the one or more synthetic CRH-R1 antagonist and/or CRH-R2 agonist comprises antalarmin.

Claim 10 (original): Pharmaceutical composition according to claim 9, wherein the one or more synthetic CRH-R1 antagonist and/or CRH-R2 agonist is antalarmin.

Claim 11 (original) Use of one or more synthetic CRH-R1 antagonists and /or CRH-R2 agonists for the manufacture of a pharmaceutical composition for the treatment of an inflammatory disease or condition associated to activation, deactivation, differentiation and apoptosis of macrophages.

Claim 12 (original): Use according to claim 11, wherein the inflammatory disease or condition is chronic inflammatory bowel disease, idiopathic in-flammatory disorder, inflammatory disorders of connective tissues, inflammatory demyelinating polyneuropathies, inflammatory myopathies, inflammatory diseases of joints including bursitis, the fibromyalgia syndrome and inflammatory diseases of upper gastrointestinal tract.

Claim 13 (original): Kit intended for the treatment of an inflammatory disease or condition comprising one or more CRH-R1 antagonists and /or CRH-R2 agonists comprised in one of more individual pharmaceutical compositions.

Claim 14 (original): Kit according to claim 13, wherein the one or more CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.